Abstracts

MPOX VIRUS SEQUENCES DIVERSITY IN PARIS AREA DURING THE 2022 OUTBREAK

Background: Since May-2022, non-endemic countries reported mpox cases with no epidemiological link to Africa, mostly affecting men-who-have-sex-with-men (MSM). We deciphered genetic variability of epidemic mpox from French infected patients and compared sequences with pre-epidemic Western-African sequences. Methods: Sequences generated from 12 PCR-amplified fragments (~30,000 base-pairs) included -outside terminal repeats- 28/35 mutation sites previously reported in…

SINGLE-VIRUS IMAGING OF HIV-1 NUCLEAR IMPORT

Background: In search of a cure for HIV infection, understanding of all molecular determinants resulting in HIV persistence is warranted. The mechanism of the early steps of HIV-1 replication including capsid uncoating, nuclear import, and integration remain poorly understood. In particular, the intracellular localization and timing of capsid uncoating is a matter of debate. Evidence…

IMPROVED GUT MICROBIOTA RECOVERY IN LATE HIV-1 PRESENTERS INITIATING DTG VS DRV/r

Background: Late HIV-1 presenters have severely impaired systemic and intestinal immune function, increased immune activation, inflammation and gut dysbiosis, reflected by loss of microbial richness and diversity alongside disbalances in commensal bacterial species. Whereas immune and inflammation parameters gradually, albeit partially, recover following antiretroviral treatment (ART) initiation, it is unknown if (a) ART initiation is…

SARS-CoV-2 INFECTIONS AMONG 275 PATIENTS WITH TIXAGEVIMAB/CILGAVIMAB PROPHYLAXIS

Background: At the end of 2021, concomitantly with the beginning of Omicron variant circulation, pre-exposure prophylaxis with the dual monoclonal long-acting monoclonal antibodies tixagevimab/cilgavimab became available in France to protect patients non-responding or non-eligible to SARS-CoV-2 vaccination at risk of severe COVID-19. Methods: This study included patients who received tixagevimab/cilgavimab for pre-exposure prophylaxis independently of…

INFLAMMASOME BUT NOT IFN-I/III RESPONSE IS ALTERED IN CHILDREN WITH LONG COVID

Background: Severe COVID-19 is less common in children than in adults. Increasing evidence show that distinct immune-pathological changes can persist weeks or months after SARS-CoV2 infection, leading to “Long COVID (LC)”. We investigated the systemic type I/III interferon (IFN-I/III) and inflammation response in peripheral blood mononuclear cells (PBMCs) of children with and without LC symptoms.…